8-K: PetVivo Inks Exclusive Deal with VetStem for Canine and Equine PRP Products

PetVivo Holdings secures an exclusive license and supply agreement with VetStem, Inc. to commercialize PrecisePRP canine and equine products, marking a significant step in veterinary regenerative medicine.

Summary

• PetVivo Holdings, Inc. has entered into an Exclusive License and Supply Agreement with VetStem, Inc. for PrecisePRP canine and equine products.
• The agreement grants PetVivo exclusive rights to sell, offer for sale, and import these therapeutic compositions.
• Exclusivity is contingent upon meeting mutually agreed-upon annual minimum purchase requirements during the first five years, with an option to extend.
• If minimum purchases are not met, the license transitions to non-exclusive for an additional two years.
• PetVivo will pay VetStem an upfront license fee of $500,000 upon execution of the agreement.
• Time milestone payments of up to $500,000 in $250,000 increments will be made at designated dates.
• Performance milestone payments of up to $500,000 in $250,000 increments will be made upon mutually agreed-upon milestones.
• PetVivo will grant VetStem 1,000,000 shares of its common stock valued at $1.0 million, priced at $1.00 per share.
• VetStem will also receive a warrant to purchase up to 250,000 shares of PetVivo's common stock at an exercise price of $1.25 per share within the first three years.
• Royalty payments will be a mutually agreed-upon percentage of Net Sales and will expire ten years after the first commercial sale or upon the expiration of the last Valid Claim of a VetStem Patent or Joint Patent.
• VetStem will manufacture and supply the products to PetVivo at a mutually agreed-upon Supply Price.
• The agreement can be terminated by either party for material breach, with a failure to cure within a specified time period.
• VetStem can terminate if PetVivo initiates a Patent Challenge action or fails to maintain at least 33% of the Minimum Purchases following a loss of Exclusivity.
• PetVivo can terminate the agreement with 90 days' written notice.
• PetVivo has an option to purchase the Assets identified in the Agreement for a mutually agreed-upon Purchase Price and an annual earn-out fee paid in the three consecutive years following the purchase of the Assets.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the exclusive licensing agreement, potential market opportunities, and positive management comments. The absence of reported adverse events in safety studies further contributes to the positive sentiment.

Positives

• The exclusive license provides PetVivo with a significant market advantage in the canine and equine PRP product space.
• PrecisePRP's off-the-shelf nature and consistent dosing offer convenience and reliability for veterinarians.
• The absence of adverse events in safety studies suggests a safe product profile.
• The agreement aligns with PetVivo's strategy to be a leader in veterinary medical devices and regenerative medicine.
• VetStem's expertise in regenerative medicine adds credibility and support to PetVivo's product line.

Negatives

• The agreement requires PetVivo to meet annual minimum purchase requirements to maintain exclusivity.
• Failure to meet these requirements could result in the license becoming non-exclusive.
• The agreement involves significant upfront and milestone payments, potentially impacting PetVivo's cash flow.
• Royalty payments based on net sales will reduce PetVivo's profit margin on PrecisePRP products.

Risks

• The success of the agreement depends on PetVivo's ability to effectively commercialize PrecisePRP products.
• Regulatory approvals and market acceptance of PrecisePRP are not guaranteed.
• Competition from existing PRP products and alternative therapies could impact sales.
• The agreement is subject to termination for material breach or other specified events.
• The company's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ significantly.

Future Outlook

The company anticipates potential benefits from the exclusive global licensing agreement with VetStem, including future payments, preclinical and clinical development activities, and market opportunities for PrecisePRP and other product candidates.

Management Comments

• Mike Eldred, PetVivo Board Member, stated that PrecisePRP will be a great addition to Spryng with OsteoCushion technology and supports their strategy to be the leader in veterinary medical devices and regenerative medicine.
• VetStem's CEO Dr. Bob Harman said that PetVivo's approach to delivering practical solutions to everyday clinical challenges is what convinced them to award them an exclusive commercialization contract for their flagship PrecisePRP products.

Industry Context

This agreement positions PetVivo to compete more effectively in the growing veterinary regenerative medicine market, particularly in the area of platelet-rich plasma (PRP) therapies. The off-the-shelf nature of PrecisePRP differentiates it from traditional PRP kits, potentially offering a competitive advantage.

Comparison to Industry Standards

• VetStem is a well-established player in the veterinary regenerative medicine field, similar to companies like Aratana Therapeutics (now Elanco Animal Health) which focused on developing and commercializing innovative therapeutics for pets.
• The PrecisePRP product is comparable to other PRP therapies available in the veterinary market, but its off-the-shelf format and consistent dosing may offer advantages over traditional PRP kits that require on-site blood processing.
• The safety studies conducted on PrecisePRP align with industry standards for evaluating the safety and efficacy of veterinary medical devices and therapeutics.

Stakeholder Impact

• Shareholders may benefit from the potential revenue growth and market expansion resulting from the agreement.
• Veterinarians will have access to a convenient and reliable PRP product for treating joint-related afflictions in dogs and horses.
• Companion animals may experience improved health and quality of life through the use of PrecisePRP therapy.

Next Steps

• PetVivo will file the Exclusive License and Supply Agreement as an exhibit to its Annual Report on Form 10-K for the quarter ended March 31, 2025.
• PetVivo will commercialize VetStem's innovative allogeneic orthobiologic products, PrecisePRP canine and PrecisePRP equine.
• PetVivo will make upfront, time milestone, and performance milestone payments to VetStem as outlined in the agreement.

Key Dates

Keywords

PetVivo, VetStem, PrecisePRP, Exclusive License, Veterinary Medicine, Regenerative Medicine, Platelet-Rich Plasma, Equine, Canine, Orthobiologic